Accord And Aspire Beat Bimatoprost Patent In The UK
Accord and Aspire have knocked down a patent barrier to bringing bimatoprost 0.1mg/ml to the UK market by convincing a Patent Court judge that the claimed formulation was obvious.
Accord and Aspire have knocked down a patent barrier to bringing bimatoprost 0.1mg/ml to the UK market by convincing a Patent Court judge that the claimed formulation was obvious.